Biovica announced that the company has signed its second US hospital agreement for DiviTum® TKa with the largest healthcare provider in Missouri, a state covering about two percent of the US population. The healthcare provider operates 18 hospitals of which one is a National Cancer Institute (NCI) Comprehensive Cancer Center and has been a partner to Biovica during the clinical development of DiviTum® TKa.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.365 SEK | +3.05% |
|
-4.64% | -8.33% |
Jun. 28 | Biovica to Provide Biomarker Testing for US Biopharmaceutical Company | MT |
Jun. 28 | Biovica International Signs New Agreement Supporting Pharma Development | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.33% | 18.88M | |
-37.33% | 8.55B | |
+14.86% | 3.8B | |
+7.38% | 2.44B | |
-25.96% | 1.87B | |
-17.30% | 1.74B | |
+36.49% | 1.19B | |
+32.58% | 830M | |
-7.64% | 711M | |
-18.37% | 589M |
- Stock Market
- Equities
- BIOVIC B Stock
- News Biovica International AB
- Biovica Signs Second Agreement with US Healthcare Provider